External
Switzerland and the UK are home to two of the world's leading life sciences and AI ecosystems, bringing together world-class research institutions, pioneering technology companies, global pharmaceutical leaders, and deep scientific and investment expertise.
AI is fundamentally reshaping the way we understand the complexities of biology. As AI evolves into a powerful engine for scientific discovery, it is creating new possibilities for how novel therapeutics are discovered and developed. Realizing this potential will require connecting world-class science, trusted data, advanced technology, investment and industry through deeper collaboration.
Hosted by the Embassy of Switzerland in London and Owkin, the UK–Switzerland Leadership Forum will convene 80-100 senior leaders from across biopharma, investment, technology, healthcare, academia and government to explore how cross-sector collaboration can advance AI-driven scientific discovery, unlock strategic partnerships and accelerate the transformation of drug R&D.
Agenda
5:30 PM – Registration & Networking
6:00 PM – Welcoming Remarks
- Dr. Dominique Paravicini, Ambassador of Switzerland to the United Kingdom
6:10–6:40 PM – Investing in AI-Driven Drug Discovery
Speakers:
- Pascal Weinberger, Co-CEO, Owkin
- Dr. Marc Moesser, Partner, Redalpine
- Vishal Gulati, Founder and Managing Partner, Recode Ventures
- Moderator: Prashant Rao, Global Managing Editor, Semafor
6:40–7:10 PM – AI, Scientific Discovery & the Future of Drug R&D
Speakers:
- Laura Haden-Smith, Director of Business Development, GSK
- Hana Aliee, Group Leader in AI, Cancer Research UK / University of Cambridge
- Lucie Friedlander, VP Commercial, Owkin
- Moderator: Prashant Rao, Global Managing Editor, Semafor
7:10 PM – Networking Reception
9:00 PM – Forum Concludes
